anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to novel musculoskeletal system related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as ' musculoskeletal system antigens', and the use of such musculoskeletal system antigens for detecting disorders of the musculoskeletal system, particularly the presence of cancer and cancer metastases. More specifically, isolated musculoskeletal system associated nucleic acid molecules are provided encoding novel musculoskeletal system associated polypeptides. Novel musculoskeletal system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human musculoskeletal system associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the musculoskeletal system, including cancer of musculoskeletal tissues, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
Obesity is the largest growing epidemic, with about 65% of Americans overweight (Flegal, Carroll et al. 2002). Obesity, in particular, abdominal obesity, confers increased risk for a host of diseases, including hypertension, Type 2 diabetes, and coronary heart disease, resulting in shortened life span (Fontaine, Redden et al. 2003). Psychological stress is widely cited anecdotally as a factor that causes people to engage in overeating, and studies provide strong evidence that stress can promote obesity. Stress induces selective preference of sweet, high-fat food and increases visceral fat depots. The telomere maintenance system (telomerase activity and telomere length)are markers of cellular aging and predict mortality (Cawthon et al, 2003)and have been linked to both psychological stress and components of the metabolic syndrome. The proposed study adapts a program called Mindfulness-Based Stress Reduction (MBSR) that has been shown to be effective in a variety of other stress-related conditions. Fifty overweight, pre-menopausal women at risk for the Metabolic Syndrome will be randomized in a 1:1 distribution to either a 3-month intervention to reduce stress and overeating \[Craving and Lifestyle Management with Mindfulness (CALMM)\] or wait list control group. The primary outcome measures include amounts of abdominal fat, weight, and telomerase activity. Data from this study are intended to provide pilot data for use in planning a larger randomized, controlled trial that will investigate the effects of the CALMM intervention on the metabolic and psychological processes assessed in this pilot study.
The invention provides a system for evaluating personal pressure risk level, which comprises a measuring unit, a questionnaire acquisition unit, a calculation processing unit and an evaluation unit. The measurement unit is used for measuring physiological data of a testee and obtaining a measurement result according to the physiological data. The questionnaire investigation unit is used for designing a questionnaire scale and obtaining a questionnaire scale result according to the questionnaire scale. The computing processing unit is used for comparing and analyzing the measurement result and the questionnaire scale result, and adjusting the questionnaire scale according to whether the comparison and analysis are abnormal and dynamic monitoring and feedback. The evaluation unit is used for calculating a pressure risk grade and a pressure risk score according to an evaluation coefficient, wherein the pressure risk score comprises a first pressure risk score corresponding to the measurement result and a second pressure risk score corresponding to the questionnaire scale result. The invention compares and analyzes the equipment measurement data and the questionnaire scale result, can dynamically monitor and compare abnormity, and can warn and remind abnormity.
Metacognitive training for depression in later life is a cognitive-behaviorally based group therapy, which focuses on helping participants gain (metacognitive) distance from their thought patterns that contribute to depression. Over 8 modules, MCT-Silver addresses issues specific to depression in later life, such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and (re-)defining values in later life and how one may move toward acceptance of situations that cannot be prevented or changed. MCT-Silver addresses cognitive and metacognitive biases that contribute to the onset and maintenance of depression through fun and engaging exercises, as well as using examples from daily life.
FIELD: medicine, homeopathy, phytotherapy. SUBSTANCE: invention relates to hydrating composition involving the following components: (a) Hydrastis canadensis (trivial name is Canadian golden-seal); (b) Ulmus fulva (trivial name is slippery elm) and (c) Smilax ornata (trivial name is green briar). Composition can be prepared in homeopathic or nonhomeopathic form. Hydrating composition in homeopathic form can be prepared by any of the following procedures. 1. Preparing separate homeopathic preparations from components (a, b and c) and their mixing. 2. Mixing extracts of components (a, b and c) and formation of homeopathic composition from obtained mixture. 3. Preparing the first homeopathic composition as in points (1) and (2) followed by dilution of the first indicated composition by addition of the second homeopathic composition. EFFECT: enhanced hydration of body, enhanced absorption of oxygen at cellular level. 16 cl, 8 ex
PURPOSE:To provide the title composition free from fear of infection through dermal scratches even if touched with fingers on a gypsum working model therefrom, comprising uncured gypsum powder, water for gypsum curing and a medical agent having anti-microorganism effect such as anti-bacterial, anti- fungal and/or anti-virus effect. CONSTITUTION:The objective composition comprising (A) uncured gypsum powder, (B) water for gypsum curing, and (C) a medical agent having anti- microorganism effect such as anti-bacterial, anti-fungal and/or anti-virus effect (e.g. sodium-p-toluenesulfonchloramide, anti-fungal zeolite). The amount of said medical agent to be incorporated is 0.05-25 pts.wt. based on 100 pts.wt. of the final composition. The present composition has such advantages that there is no infectious fear even if scattered gypsum dust produced by machining a working model therefrom such as a dental handpiece is ingested into the human body, no fear of impairing the surface of gypsum or declining its mechanical properties compared to the case with conventional sterilizing processes, and no adverse effect on human health.
BACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative brain disease due to degeneration of dopaminergic neurons (DNs) presented with motor and non-motor symptoms. PD symptoms are developed in response to the disturbance of diverse neurotransmitters including γ-aminobutyric acid (GABA). GABA has a neuroprotective effect against PD neuropathology by protecting DNs in the substantia nigra pars compacta (SNpc). It has been shown that the degeneration of GABAergic neurons is linked with the degeneration of DNs and the progression of motor and non-motor PD symptoms. GABA neurotransmission is a necessary pathway for normal sleep patterns, thus deregulation of GABAergic neurotransmission in PD could be the potential cause of sleep disorders in PD.
AIM: Sleep disorders affect GABA neurotransmission leading to memory and cognitive dysfunction in PD. For example, insomnia and short sleep duration are associated with a reduction of brain GABA levels. Moreover, PD-related disorders including rigidity and nocturia influence sleep patterns leading to fragmented sleep which may also affect PD neuropathology. However, the mechanistic role of GABA in PD neuropathology regarding motor and non-motor symptoms is not fully elucidated. Therefore, this narrative review aims to clarify the mechanistic role of GABA in PD neuropathology mainly in sleep disorders, and how good GABA improves PD. In addition, this review of published articles tries to elucidate how sleep disorders such as insomnia and REM sleep behavior disorder (RBD) affect PD neuropathology and severity. The present review has many limitations including the paucity of prospective studies and most findings are taken from observational and preclinical studies. GABA involvement in the pathogenesis of PD has been recently discussed by recent studies. Therefore, future prospective studies regarding the use of GABA agonists in the management of PD are suggested to observe their distinct effects on motor and non-motor symptoms.
CONCLUSION: There is a bidirectional relationship between the pathogenesis of PD and sleep disorders which might be due to GABA deregulation.
Flowering plant genomes encode four or five DICER-LIKE (DCL) enzymes that produce small interfering RNAs (siRNAs) and microRNAs, which function in RNA interference (RNAi). Different RNAi pathways in plants effect transposon silencing, antiviral defense, and endogenous gene regulation. DCL2 acts genetically redundantly with DCL4 to confer basal antiviral defense. However, DCL2 may also counteract DCL4 since knockout of DCL4 causes growth defects that are suppressed by DCL2 inactivation. Current models maintain that RNAi via DCL2-dependent siRNAs is the biochemical basis of both effects. Here, we report that DCL2-mediated antiviral resistance and growth defects cannot be explained by the silencing effects of DCL2-dependent siRNAs. Both functions are defective in genetic backgrounds that maintain high levels of DCL2-dependent siRNAs, either with specific point mutations in DCL2 or with reduced DCL2 dosage because of heterozygosity for dcl2 knockout alleles. Intriguingly, all DCL2 functions require its catalytic activity, and the penetrance of DCL2-dependent growth phenotypes in dcl4 mutants correlates with DCL2 protein levels but not with levels of major DCL2-dependent siRNAs. We discuss this requirement and correlation with catalytic activity but not with resulting siRNAs, in light of other findings that reveal a DCL2 function in innate immunity activation triggered by cytoplasmic double-stranded RNA.
INTRODUCTION: The Sauvé-Kapandji (SKp) procedure is a frequently used surgery for the management of post-traumatic sequelae of the distal radio-ulnar joint (DRU). Series evaluating long-term outcomes and the risk of complications are rare. The main objective was to describe the long-term clinical and radiographic results after SKp performed in a post-traumatic context. The secondary objectives were to identify postoperative complications, surgical revisions, and their risk factors for occurrence. Our hypothesis was that although SKp confers good clinical results, identifiable risk factors for complications exist.
PATIENTS AND METHODS: This monocentric retrospective study included all patients for whom an SKp was performed in a post-traumatic context from 2008 to 2018. Pain, satisfaction, range of motion and pre- and postoperative radiographic measurements were recorded. All complications were sought and described, as well as surgical revisions. Several variables were analysed to identify risk factors for revision surgery after SKp: age, sex, initial traumatic mechanism, initial non-surgical or surgical treatment and type of surgery, time until revision surgery with SKp after the initial trauma.
RESULTS: Thirty-seven patients were included. At a median follow-up of 9.5 years (min 7.3-max 11.5), 22 patients (60%) had a VAS of 0. Range of motion was significantly improved for all the patients (p<0.001). Seventeen (46%) patients had a complication, including 5 (13.4%) cases of ossification, 4 (10.8%) cases of discomfort related to the hardware and 4 (10.8%) painful instability at the proximal ulnar stump. Thirteen (35%) patients required revision surgery. Two risk factors for revision surgery after SKp were found: time period between initial treatment and SKp of less than 7.2 months and an age of less than 53.5 years; the combination of the two factors having a sensitivity of 97.5 and a specificity of 56.7.
CONCLUSION: SKp in a post-traumatic context significantly improved range of motion and allowed pain control at long follow-up. Revision surgery seemed more frequent in patients under 53.5 years of age and when SKp was performed less than 7.2 months after the initial trauma.
LEVEL OF EVIDENCE: IV, retrospective study.
The present invention relates to a composition for preventing or treating skin inflammation and skin diseases, the composition comprising WKYMVm or an HA-WKYMVm conjugate as an active ingredient. The HA-WKYMVm conjugate, which is a conjugate of WKYMVm and hyaluronic acid (HA), showed an excellent hair growth promotion effect compared to WKYMVm when administered transdermally through application onto the skin rather than subcutaneous injection. In addition, the HA-WKYMVm conjugate ameliorated scleroderma by suppressing skin inflammatory responses in inflammatory scleroderma model mice through transdermal administration. Therefore, the WKYMVm and the HA-WKYMVm conjugate, according to the present invention, can be effectively used in medical, pharmaceutical and cosmetics-related industries related to the prevention or treatment of skin inflammation and skin diseases. Also, the present invention relates to a composition for preventing or treating skin inflammation and skin diseases, the composition comprising an HA-WKYMVm conjugate as an active ingredient. The WKYMVm according to the present invention exhibited a hair growth promotion effect in alopecia model mice.
Local Reactions \- As with other insulin therapy, patients may experience redness, swelling, or itching at the site of NovoLog injection. These reactions usually resolve in a few days to a few weeks, but in some occasions, may require discontinuation of NovoLog. In some instances, these reactions may be related to factors other than insulin, such as irritants in a skin cleansing agent or poor injection technique. Localized reactions and generalized myalgias have been reported with injected metacresol, which is an excipient in NovoLog.

Systemic Reactions \- Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with any insulin product, including NovoLog. Anaphylactic reactions with NovoLog have been reported post-approval. Generalized allergy to insulin may also cause whole body rash (including pruritus), dyspnea, wheezing, hypotension, tachycardia, or diaphoresis. In controlled clinical trials, allergic reactions were reported in 3 of 735 patients (0.4%) treated with regular human insulin and 10 of 1394 patients (0.7%) treated with NovoLog. In controlled and uncontrolled clinical trials, 3 of 2341 (0.1%) NovoLog-treated patients discontinued due to allergic reactions.
ASD CB-MNC infusion from different donors and standard therapy. CBU with 3 or less HLA compatibility degree in A, B, DRB1 loci will be used.
NEW MATERIAL:A compound of formula I (R is the residue of a carboxylic acid-type non-steroidal antiphlogistic analgesic agent). EXAMPLE:5-Hydroxy-2-(3-benzoyl-phenyl-methylpropionate)-4H-pyrane-4-one. USE:A melamine production-inhibiting agent, or an antiinflammatory, analgestic and antithrombogenic agent. The compound of formula I has good photostability and is useful for drugs and cosmetics. PREPARATION:Kojic acid is allowed to react with a halogenating agent (e.g. thionyl chloride or phosphorus pentachloride) in an organic solvent (e.g. benzene, toluene, THF, chloroform) at 0 deg.C-200 deg.C, preferably 10-100 deg.C, for 0.5-10 hours to prepare a 2-methylchloro compound of formula II. The compound of formula II is subjected to a reaction with a carboxylic acid non-steroidal antiphlogestic analgesic agent in the presence of an alkali catalyst in a solvent such as DMF or THF at 0 deg.C-200 deg.C, preferably at 10-100 deg.C, to prepare the compound of formula I.
FIELD: medicine, surgery. SUBSTANCE: before and after elimination of purulentnecrotic inflammation one should apply furred animal's fat onto wound surface once daily at 0.1 cm thickness till complete healing. One should use fat of marmots, raccoons, minks or polar foxes. The method provides efficient treatment of wounds and ulcers being simple and cheap during usage. EFFECT: higher efficiency of therapy. 4 cl, 2 ex
The patient was a 51-year-old man who had undergone living donor liver transplantation for type B cirrhosis at the age of 37 years, and had a history of immunosuppressive drug use. He had developed focal seizures starting from his right upper limb, and MRI showed a lesion in the subcortical white matter of his left parietal lobe. Sensory disturbance and paralysis progressed in his right upper and lower limbs, and his brain lesion rapidly enlarged. A brain biopsy revealed diffuse large B-cell lymphoma, and Epstein-Barr virus-encoded small RNA in situ hybridization was positive. The patient was diagnosed with primary central nervous system post-transplant lymphoproliferative disorder (PCNS-PTLD) with no lesions in other organs. There are few reports of PCNS-PTLD cases after living donor liver transplantation in Japan. Although rare, it is nevertheless important to consider this disease in patients receiving immunosuppressive drugs after organ transplantation who develop brain lesions, regardless of which organ was transplanted.
Anonymous ampoule containing 5 ml of 100 mg/ml Tranexamic Acid. If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
Sleep plays an essential role in individual energy conservation and disease prognoses. However, sleep disturbance is a common problem in intensive care and is associated with adverse effects. The factors that cause sleep disturbance in critically ill patients are complex and include both internal and external factors. Furthermore, the effects of sleep disturbance are not limited to intensive care units as the condition may persist after discharge. Therefore, sleep disturbance cannot be ignored and deserves greater research attention. Based on a literature review, this article describes the theoretical mechanisms, factors, influences, and subjective and objective assessment tools related to sleep in critically ill patients. The pharmacological and non-pharmacological strategies introduced in this study may be referenced by clinical medical professionals to better understand sleep disturbance in critically ill patients and promote effective sleep care for this vulnerable population.
BACKGROUND: Continuum of care (CoC) for maternal and child health provides opportunities for mothers and children to improve their nutritional status, but many children remain undernourished in Angola. This study aimed to assess the achievement level of CoC and examine the association between the CoC achievement level and child nutritional status.
METHODS: We used nationally representative data from the Angola 2015-2016 Multiple Indicator and Health Survey. Completion of CoC was defined as achieving at least four antenatal care visits (4 + ANC), delivery with a skilled birth attendant (SBA), child vaccination at birth, child postnatal check within 2 months (PNC), and a series of child vaccinations at 2, 4, 6, 9 and 15 months of child age. We included under 5 years old children who were eligible for child vaccination questionnaires and their mothers. The difference in CoC achievement level among different nutritional status were presented using the Kaplan-Meier method and examined using the Log-Lank test. Additionally, the multivariable logistic regression analysis examined the associations between child nutritional status and CoC achievement levels.
RESULTS: The prevalence of child stunting, underweight and wasting was 48.3%, 23.2% and 5.9% respectively. The overall CoC completion level was 1.2%. The level of achieving CoC of mother-child pairs was 62.8% for 4 + ANC, 42.2% for SBA, 23.0% for child vaccination at birth, and 6.7% for PNC, and it continued to decline over 15 months. The Log-Lank test showed that there were significant differences in the CoC achievement level between children with no stunting and those with stunting (p < 0.001), those with no underweight and those with underweight (p < 0.001), those with no wasting and those with wasting (p = 0.003), and those with malnutrition and those with a normal nutritional status (p < 0.001). Achieving 4 + ANC (CoC1), 4 + ANC and SBA (CoC 2), and 4 + ANC, SBA, and child vaccination at birth (CoC 3) were associated with reduction in child stunting and underweight.
CONCLUSIONS: The completion of CoC is low in Angola and many children miss their opportunity of nutritional intervention. According to our result, improving care utilization and its continuity could improve child nutritional status.
Calpain is a non-lysozyme, calcium-dependent intracellular cysteine protease that has been shown to play a role in tumor proliferation, survival, migration, invasion, and apoptosis. Dysregulation of calpain expression is closely related to tumorigenesis. However, the role of calpain-8 (CAPN8), as a member of the calpain family, in pancreatic cancer (PC) is remains unclear. In elucidating the mechanism of CAPN8 in PC, a comprehensive bioinformatics analysis and in vitro experiments were conducted. The TCGA database was used to explore the expression level of CAPN8, and the results in PC tissues and cell lines were verified. Then, the correlation between CAPN8 and clinicopathological features was analyzed. Additionaly, promoter methylation, immune infiltration, and GO/KEGG enrichment analyses were performed. Lastly, the molecular mechanism of CAPN8 in PC was investigated by using cell counting kit (CCK) 8, transwell, wound healing, Western blot assays, and so on. Results indicate that CAPN8 was highly expressed in PC and correlated with poor prognosis and advanced TNM stage. In addition, a low level of immune infiltration was closely associated with the high expression level of CAPN8. Based on these findings, we hypothesized that CAPN8 is a potential biomarker that regulates progression of PC via EMT and the AKT/ERK pathway. SIGNIFICANCE: Through comprehensive biological information and in vitro experiments, CAPN8 has been confirmed to play an important role in regulating pancreatic cancer (PC) proliferation, migration and invasion. CAPN8 is found to be closely related to the diagnosis, survival and prognosis of PC. Above all, CAPN8 may be a potential biomarker for the diagnosis and prognosis of PC.